ClinConnect ClinConnect Logo
Search / Trial NCT05527717

Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator

Launched by SAMSUNG MEDICAL CENTER · Aug 31, 2022

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at the best way to treat patients who have a serious heart attack (called acute myocardial infarction) and are also experiencing a condition known as cardiogenic shock, which means their heart is struggling to pump enough blood. The researchers want to find out if performing immediate treatment on all blocked arteries (known as multi-vessel PCI) is better than just treating the one that caused the heart attack (culprit lesion-only PCI) for patients needing a special heart-lung machine called veno-arterial extracorporeal membrane oxygenation (VA-ECMO).

To participate in this trial, patients must be at least 19 years old and have a heart attack with cardiogenic shock, requiring VA-ECMO. They must also have multiple blocked arteries that can be treated with a procedure called primary PCI. The study is currently recruiting participants, and all genders are welcome to join. If eligible, participants will receive either type of treatment and will help researchers understand which approach leads to better health outcomes. It’s important for potential participants to know that those with certain other health issues or complications won't be eligible for this study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject must be at least 19 years of age
  • Patients presented with AMI (ST-segment elevation MI \[STEMI\] or non-ST-segment elevation MI \[NSTEMI\]) complicated by CS (SCAI Shock classification C, D or E) who requiring VA-ECMO.
  • Target lesions amenable for planned primary PCI by operators' decision
  • Patients with multi-vessel disease
  • Exclusion Criteria:
  • Other causes of shock (hypovolemia, sepsis, obstructive shock).
  • Shock due to mechanical complication to MI (rupture of papillary muscle, the ventricular septum, or free wall).
  • Unwitnessed out of hospital cardiac arrest with persistent Glasgow coma scale \<8 after the return of spontaneous circulation.
  • Patients with single-vessel disease (Patients with single-vessel disease will be enrolled in the RESCUE-SHOCK registry)
  • Onset of shock \>24 hours.
  • Known heparin intolerance.
  • Other severe concomitant disease with limited life expectancy \< 6 months
  • Pregnancy or breast feeding
  • Do not resuscitate wish

About Samsung Medical Center

Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.

Locations

Seoul, , Korea, Republic Of

Patients applied

0 patients applied

Trial Officials

Jeong Hoon Yang, MD

Principal Investigator

Samsung Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials